氨基苷类药物在抗结核治疗中的肾毒性分析  

Nephrotoxicity analysis of aminoglycosides in antituberculosis therapy

作　　者：杨华锋 彭云龙 YANG Huafeng;PENG Yunlong(The First People＇s Hospital of Yidu,Hubei Province,Yidu 443300,China)

机构地区：[1]湖北省宜都市第一人民医院,443300

出　　处：《临床合理用药杂志》2018年第25期8-9,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的分析在抗结核治疗中应用氨基苷类药物造成的肾毒性。方法选取医院收治的结核病患者165例,依据应用的氨基苷类药物种类分为A组42例、B组38例、C组40例和D组45例,比较4组患者治疗前后血清肌酐清除率。结果治疗前4组患者的血清肌酐清除率比较差异无统计学意义(P>0.05);治疗后4组患者血清肌酐清除率均无显著变化(P>0.05),且组间比较差异均无统计学意义(P>0.05)。结论氨基苷类药物应用于结核病患者的抗结核治疗中安全性高,对患者的肾功能损伤小,值得临床推广,但要控制用药剂量和用药时间。Objective To analyze the nephrotoxicity caused by the application of aminoguanidine drugs in anti-tuberculosis treatment. Methods 165 cases of patients with tuberculosis admitted to the hospital were selected,according to the type of aminoguanidine drugs used,they were divided into four groups,A group（ 42 cases）,B group（ 38 cases）,C group（ 40 cases）,D group（ 45 cases）,the serum creatinine clearance rate before and after treatment was compared between the four groups. Results There was no significant difference in serum creatinine clearance between the four groups before treatment（ P 〉0. 05）. There was no significant change in serum creatinine clearance in the four groups after treatment（ P〉 0. 05）,and there was no significant difference between the groups（ P 〉0. 05）. Conclusion Aminoglycoside drugs used in tuberculosis patients with anti-tuberculosis treatment of high safety,renal damage to patients is small,and it can be clinically adopted and vigorously promote,but to control the dosage and medication time.

关 键 词：结核病 氨基苷类药物 肾毒性 

分 类 号：R969.3[医药卫生—药理学]